Recursion Pharmaceuticals Inc (RXRX NASDAQ) stock market data APIs
$4.6674
-0.02(-0.4%)
as of May 12, 2025
Try our APIs with
free plan!
Recursion Pharmaceuticals Inc Financial Data Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Prev. Close
4.6674
Open
4.6428
High
4.6902
Low
4.3845
52 wk Range
3.79-12.36
Market Cap
1 886 M
Shares Outstanding
400 M
Revenue
59 790 K
EPS
-0.5
Beta
0.984
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Recursion Pharmaceuticals Inc data using free add-ons & libraries
Get Recursion Pharmaceuticals Inc Fundamental Data
Recursion Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 59 790 K
- EBITDA: -525 584 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.516
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Recursion Pharmaceuticals Inc News
New
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
Key Points Artificial intelligence (AI) is the defining technological innovation of our age. AI stocks have soared over the past two years, yet some companies remain compelling bargains. These two AI...
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
Key Points The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported le...
Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43
Shareholders in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) had a terrible week, as shares crashed 27% to US$4.16 in the week since its latest first-quarter results. It wasn't the greatest result, w...
Recursion axes drug programmes to streamline pipeline
AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with fello...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
